My name is Yvonne Brandberg and I work at the Karolinska Institute in Stockholm.The PANTHER trial was started in order to evaluate effects of tailoredand dose-dense therapy, both these concepts in order to improve efficacyof chemotherapy.The same pattern occurred for almost all the subscalesconcerning Quality of Life.From the beginning it decreased and then when treatment stoppedthe level of Quality of Life improved.So they have better Quality
of Life after treatment.But there were also differences between the randomization arms.One group was randomized to
dose-dense and tailored therapyand the other one to
standard chemotherapy.And those in the dose-dense group had lower levels of Quality of Lifeduring treatment.It was a global Quality of Life
overall Quality of Life.And also physical functioning, role functioning, social functioningand fatigue, systemic therapy side effects of sexual functioning.I think that the instruments worked well and that can be shownby the fact that we found differences on this case where we expect the differences.But for instance, for arm and breast problems there were no differencesbetween the groups.And [inaudible] are developed for use in clinical breast cancer trials.The problem is compliance.And in multi-[inaudible] studies
it's difficult to collect dataso we had a lot of missing
data from Germany and Austria.I think it's important to use this information from the trials and informthe patients that you might feel bad and your Quality of Life might godown during treatment but once you stop, then it returns to similar levelsif you have the other treatment, and also that makes people want to tryto have this treatment.